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Small ubiquitin-like modiﬁer (SUMO)-speciﬁc proteases
(SENPs) that reverse protein modiﬁcation by SUMO are
involved in the control of numerous cellular processes,
including transcription, cell division, and cancer develop-
ment. However, the physiological function of SENPs in
energy metabolism remains unclear. Here, we investigated
the role of SENP2 in fatty acid metabolism in C2C12
myotubes and in vivo. In C2C12 myotubes, treatment with
saturated fatty acids, like palmitate, led to nuclear factor-kB–
mediated increase in the expression of SENP2. This increase
promoted the recruitment of peroxisome proliferator–
activated receptor (PPAR)d and PPARg, through desu-
moylation of PPARs, to the promoters of the genes
involved in fatty acid oxidation (FAO), such as carnitine-
palmitoyl transferase-1 (CPT1b) and long-chain acyl-CoA
synthetase 1 (ACSL1). In addition, SENP2 overexpression
substantially increased FAO in C2C12 myotubes. Consis-
tent with the cell culture system, muscle-speciﬁc SENP2
overexpression led to a marked increase in the mRNA
levels of CPT1b and ACSL1 and thereby in FAO in the
skeletal muscle, which ultimately alleviated high-fat diet–
induced obesity and insulin resistance. Collectively, these
data identify SENP2 as an important regulator of fatty acid
metabolism in skeletal muscle and further implicate that
muscle SENP2 could be a novel therapeutic target for the
treatment of obesity-linked metabolic disorders.
Insulin resistance precedes the development of type 2
diabetes mellitus and is characterized by impaired
insulin-dependent glucose metabolism in metabolically
active tissues, such as skeletal muscle, liver, and adipose
tissues. Among these tissues, skeletal muscle is one of the
major sites that expend glucose. There is a negative
relationship between muscle triglyceride levels and insulin
sensitivity (1–4), and insulin sensitivity is reduced by
fatty acid overload in cultured myocytes (5). Several trials
to increase fatty acid oxidation (FAO) or to limit fat
storage in muscle have been shown to improve obesity-
induced insulin resistance (6–9), which can be applied for
the treatment of insulin resistance.
Peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear receptor superfamily and
comprise three isoforms: PPARa, PPARd, and PPARg. All
are involved in lipid metabolism and glucose homeostasis,
although they show different tissue distributions and
physiological roles (10). PPARd is expressed ubiquitously
in all tissues, and its agonists facilitate FAO in skeletal
muscle via PPARg coactivator (PGC)1a (11). PPARg is
highly expressed in adipocytes and plays an essential
role in adipogenesis (12).
Small ubiquitin-like modiﬁer (SUMO) is conjugated to
a variety of proteins and modulates their localization,
stability, and interaction with other proteins (13,14).
SUMO modiﬁcation (sumoylation) is involved in the con-
trol of various cellular processes, including cell cycle pro-
gression, gene expression, and signal transduction (15,16).
Sumoylation can be reversed by the action of SUMO-
speciﬁc cysteine proteases (SENPs). Six mammalian SENP
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family members have been identiﬁed, and they have dif-
ferent subcellular locations and substrate speciﬁcity
(17–20). SENPs also play important roles in the control
of various cellular events. Knockout of either SENP1 or
SENP2 results in embryonic lethality (21–23), suggesting
that the regulation of sumoylation is essential for de-
velopmental processes. Moreover, disruption of SUMO
homeostasis contributes to the development and pro-
gression of prostate cancer, in which SENP1 and SENP3
are critically involved (24–26). It is also known that
SENP2 desumoylates Mdm2, an ubiquitin E3 ligase of
p53, and contributes to the control of p53-mediated pro-
cesses (27). However, relatively little is known about the role
of SENPs in the regulation of energy metabolism. Recent
studies have shown that SENP2 represses glycolysis and
reprograms glucose metabolism in cancer cells and SENP1
overexpression increases mitochondrial biogenesis in
myotubes (28,29).
Several transcription factors involved in metabolic regu-
lation, such as PPARg and PGC1a, are known to serve as
targets for sumoylation (30,31). We have recently shown
that SENP2 desumoylates PPARg and dramatically increases
the activity of PPARg (32). Interestingly, the sumoylation
status of PPARg selectively regulates the expression of
some PPARg target genes in myotubes: desumoylation of
PPARg increases the mRNA level of fatty acid translocase
(CD36) but not of adipose differentiation-related protein
(ADRP), although both are upregulated by PPARg agonists.
Based on these reports, we hypothesized that SENP2 is in-
volved in metabolic regulation in skeletal muscle. In this study,
we investigated the potential role of SENP2 in the regulation
of fatty acid metabolism in skeletal muscle by using a cultured
cell system and a genetically engineered animal model.
RESEARCH DESIGN AND METHODS
Materials
Expression vectors for PPARs, SUMO-1, SENPs, ubiquitin
conjugating enzyme 9 (UBC9), and PPAR response element-
thymidine kinase-luciferase (PPRE-TK-Luc) reporter vector
(pPPRE-TK-Luc) were prepared as previously described
(32). An expression vector for PGC1a was obtained from
Dr. Gang Xu (The Chinese University of Hong Kong, Hong
Kong). Reporter vectors for SENP2 were also generated:
(21980)-Luc, (2868)-Luc, and (2157)-Luc (33). Muta-
tions in the nuclear factor-kB (NF-kB) binding site of
(2157)-Luc were generated by substituting GGG (270
to 268 bp) with CTC. Adenovirus containing the human
SENP2 expression construct (Ad-SENP2) was prepared as
previously described (32). All small interfering (si)RNAs
were purchased from Dharmacon except for PPARg
siRNA (Invitrogen). Polyclonal antibody against SENP2
was produced using the peptide representing amino acid
317–335 of mouse SENP2 as an epitope (Abclon, Korea).
Cell Culture and Transfection
C2C12 myoblasts were maintained in DMEM supple-
mented with 10% FBS (Invitrogen). Differentiation was
induced using DMEM containing 2% horse serum
(Invitrogen) for 4 days. Transfection of plasmids was
performed using Lipofectamin with Plus Reagent (Invi-
trogen), and siRNAs were transfected using RNAiMAX
(Invitrogen).
RNA Preparation and Real-Time PCR
Total RNAs were isolated by using TRIzol (Invitrogen), and
real-time PCR was performed using SYBR-master mix (Takara)
and ABI 7500 real-time PCR system (Applied Biosystems).
Nucleotide sequences of the primers are shown in Supple-
mentary Table 1.
Measurement of Fatty Acid Oxidation
For measurement of FAO, muscle tissues or cells were
homogenized in an ice-cold mitochondria isolation buffer
(250 mmol/L sucrose, 10 mmol/L Tris-HCl, and 1 mmol/L
EDTA). The lysates were incubated for 2 h with 0.2
mmol/L [1-14C]palmitate. 14CO2 and
14C-labeled acid-soluble
metabolites were quantiﬁed using a liquid scintillation counter.
Each radioactivity was normalized by protein amount of each
lysate.
Electrophoretic-Mobility Shift Assays
The probe was labeled with biotin and incubated with
nuclear extracts from C2C12 myotubes treated with
palmitate for 24 h in the binding buffer (LightShift
Chemiluminescent electrophoretic-mobility shift assay
[EMSA] kit). The sequences of the probe and competitors
are shown in Supplementary Table 1.
Chromatin Immunoprecipitation Coupled With
Quantitative PCR
After cross-linking and DNA fragmentation, nuclear extracts
were subjected to immunoprecipitation with antibodies
against PPARa, PPARd, PPARg, PGC1a, and control IgG.
The sequences of primers are listed in Supplementary Table 1.
Microarray
Gene expression of C2C12 cells was proﬁled using MouseRef-
8-v2-BeadChip (Illumina). The array was scanned using
a BeadStation 500 System (Illumina).
Animals and Metabolic Analyses
All aspects of animal care and experimentation were
conducted in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH publ. no. 85-23, revised 1996). The mice were DXA
scanned using a LUNAR Prodigy scanner with software
version 8.10 (GE Healthcare). The levels of free fatty acid
and triglyceride were measured (BioVision). For electron
microscopical analysis, thin muscle sections were pre-
pared and examined using a transmission electron micro-
scope (JEM-1400) at 80 Kv.
Statistical Analysis
Statistical analysis was performed using SPSS version 12.0
(SPSS Inc.). Statistical signiﬁcance was tested using the
Mann-Whitney U test. A P value ,0.05 was considered
statistically signiﬁcant.
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RESULTS
Palmitate Elevates the Expression of SENP2 in C2C12
Myotubes
In an attempt to identify the factor(s) that regulates SENP2
expression, C2C12 myotubes were treated with various
metabolites, hormones, and cytokines. The expression of
SENP2 mRNA was not signiﬁcantly changed upon treat-
ment with insulin, glucose, interleukin-6, or tumor necrosis
factor-a (Supplementary Fig. 1). However, it was markedly
increased by treatment with palmitate (Fig. 1A), and this
increase occurred in dose- and incubation time–dependent
fashions, respectively (Fig. 1B and C). Increase in the SENP2
protein levels by palmitate was also conﬁrmed (Supplemen-
tary Fig. 1B). On the other hand, unsaturated fatty acids,
such as oleate, linoleate, and eicosapentaenoic acid, showed
little or no effect on the SENP2 mRNA levels (Fig. 1A). In
addition, the expression of SENP1, another SENP, was not
inﬂuenced by any of the tested fatty acids, including palmi-
tate (Supplementary Fig. 1C), suggesting that palmitate spe-
ciﬁcally regulates the expression of SENP2 in myotubes.
SENP2 Expression Is Regulated by Palmitate-Induced
NF-kB Activation
Palmitate is known to induce NF-kB activation (34,35). It
has also been shown that toll-like receptor 4 (TLR4)
and MyD88 are responsible for palmitate-induced NF-kB
activation (34,36,37). Treatment with pyrrolidine dithio-
carbamate, a selective NF-kB inhibitor, abrogated palmitate-
mediated increase in the mRNA level of SENP2 (Fig. 1D).
Consistently, knockdown of NF-kB by speciﬁc siRNAs (con-
ﬁrmed at Supplementary Fig. 2A) completely inhibited the
effect of palmitate on the SENP2 mRNA level (Fig. 1E).
Moreover, knockdown of TLR4 or MyD88 (conﬁrmed at
Supplementary Fig. 2B) led to suppression of palmitate-
induced expression of SENP2 mRNA (Fig. 1F). These
results suggest that the increase in the SENP2 mRNA level
is mediated by palmitate-induced NF-kB activation via
TLR4 and MyD88.
For determination of whether the promoter of the mouse
SENP2 gene has a cis-acting element for NF-kB–mediated
regulation, its 59-ﬂanking region was serially deleted and
inserted into a Luc reporter vector. Palmitate treatment
led to three- to fourfold increase in the Luc activity upon
transfection of the constructs having the regions from
21980, 2868, and 2157 to +93 bp (Fig. 1G). Furthermore,
a potential NF-kB–binding sequence was found to locate at
~70 bp upstream of the transcription start site (as shown at
Fig. 1H) and mutations of the sequence abrogated palmitate-
induced promoter activity (Fig. 1G). To conﬁrm this ﬁnding,
we performed EMSA by using nuclear extracts of C2C12
myotubes. Palmitate treatment led to a dramatic increase
in a binding with a biotin-labeled probe containing the pu-
tative NF-kB–binding sequence (Fig. 1H, lane 3), and this
increased binding could be abolished by treatment with the
same but unlabeled probe (lane 4) as well as with the un-
labeled consensus NF-kB–binding sequence (lane 6), but not
with a oligonucleotide having the mutated sequence (lane 5).
Furthermore, the band was supershifted by addition of anti–
NF-kB antibody (lane 7). These results suggest that the
SENP2 promoter has a cis-acting element for palmitate-
induced NF-kB binding.
SENP2 Promotes Palmitate-Mediated Increase in the
Expression of Acyl-CoA Synthetase 1, Carnitine-
Palmitoyl Transferase 1b, and UCP3
Long-chain acyl-CoA synthetase (ACSL)1 and carnitine-
palmitoyl transferase (CPT)1 are known to play a critical
role in FAO (38,39). In addition, uncoupling protein
(UCP)3 has also been shown to augment FAO (40,41).
Henceforth, we referred to ACSL1, CPT1b, and UCP3 as
FAO-associated enzymes. Palmitate treatment led to an
increase in the mRNA levels of FAO-associated enzymes
in a dose-dependent fashion (Fig. 2A). Furthermore,
knockdown of SENP2 (Supplementary Fig. 3) suppressed
the increase in the mRNA levels of all three proteins (Fig.
2B). Consistently, palmitate-stimulated FAO was abro-
gated by SENP2 knockdown (Fig. 2C). These results sug-
gest that SENP2 plays a crucial role in the control of FAO
under conditions with overloaded saturated fatty acids.
Overexpression of SENP2 Increases FAO Primarily By
Upregulating the Expression of FAO-Associated
Enzymes
We performed mRNA microarray analysis using C2C12
myotubes that had been infected with adenovirus over-
expressing SENP2 (Ad-SENP2). Remarkably, the mRNA
levels of the proteins involved in the metabolic process of
fatty acids (including ACSL1, CPT1b, and UCP3) as well as of
glucose were dramatically upregulated (Fig. 3A). Interestingly,
however, the mRNA levels of the proteins involved in cell
cycle and DNA replication were markedly downregulated by
SENP2 overexpression. These results indicated that SENP2 is
functionally related to energy metabolism in myotubes.
For further conﬁrmation of this ﬁnding, C2C12 myo-
tubes were infected with Ad- SENP1, Ad-SENP2, and its
catalytically inactive form (C548S) (Ad-SENP2mt) (Supple-
mentary Fig. 4A and B). Consistent with the data from
microarray analysis, overexpression of SENP2, but not
SENP1 or SENP2mt, led to an increase in the mRNA levels
of FAO-associated enzymes (Fig. 3B). Moreover, the increase
in FAO by overexpression of SENP2 was signiﬁcantly higher
than that by overexpression of SENP1 or SENP2mt (Fig.
3C). On the other hand, overexpression of SENP2 showed
little or no effect on the expression of mRNAs for transcrip-
tion factors involved in lipid metabolism, such as PPARa,
PPARd, PPARg, PGC1a, and estrogen-related receptor a
(Supplementary Fig. 4C). These results suggest that the
desumoylating activity of SENP2 is required for the promo-
tion of FAO via upregulation of the expression of FAO-
associated enzymes in C2C12 myotubes.
SENP2 Increases FAO Mainly by Promoting PPARd-
and PPARg-Mediated Expression of FAO-Associated
Enzymes
To determine whether SENP2-dependent increase in the
expression of FAO-associated enzymes is mediated by
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desumoylation of transcription factors that are involved
in lipid metabolism, we ﬁrst performed knockdown
analysis of each of them. Supplementary Fig. 4D shows
that each siRNA used effectively depletes the mRNA of its
target transcription factor (i.e., PPARa, PPARd, PPARg,
PGC1a, estrogen-related receptor a, and receptor-
interacting protein 140). Interestingly, knockdown of
PPARd and PPARg, but not of the others, dramatically
Figure 1—Expression of SENP2 mRNA is regulated by palmitate-induced NF-kB activation. A: C2C12 myotubes were treated with various
fatty acids (0.5 mmol/L) for 24 h. Free fatty acids (100 mmol/L in EtOH) were diluted in the culture medium containing fatty acid–free BSA in
a 1:3 molar ratio. The mRNA levels of SENP2 were then determined by real-time PCR. Each Ct value was subtracted by Ct value of GAPDH
(DCt) and then subtracted by the DCt of each control set (ddCt). Relative mRNA levels were expressed as 22ddCt. The SENP2 mRNA level of
untreated cells (vehicle [Veh]) was expressed as 1.0, and the others were expressed as its relative values. Data are the mean 6 SEM of ﬁve
independent experiments. *P < 0.05. B: C2C12 myotubes were treated with increasing amounts of palmitate for 24 h (n = 4). *P < 0.05
compared with untreated cells (Veh). C: C2C12 myotubes were treated with 0.5 mmol/L palmitate for increasing periods and then subjected
to assay for SENP2 mRNA levels (n = 5). *P < 0.05 compared with untreated cells. D: C2C12 myotubes were treated with palmitate in the
absence or presence of 10 mmol/L pyrrolidine dithiocarbamate (n = 4). *P < 0.05. E: C2C12 myotubes were transfected with siRNA against
NF-kB (50 nmol/L) for 24 h and then treated with palmitate for 24 h (n = 3). *P < 0.05. F: C2C12 myotubes transfected with the indicated
siRNAs were treated with palmitate (n = 4). *P < 0.05. G: C2C12 myoblasts were transfected with Luc reporter vectors harboring various
deletions of promoter region in the SENP2 gene. After treatment with palmitate for 24 h, they were subjected to assay for Luc activity (n = 4).
The arrowhead indicates the mutations shown inH. The Luc activity of the cells transfected with (21980)-Lucwithout palmitate was set to 1, and
the other values were expressed relative to that. *P< 0.05 compared with untreated cells; #P< 0.05. H: The putative NF-kB–binding sequence
in the SENP2 promoter (285 bp to254 bp) is underlined in “Self.” The underline in “Con” (consensus) indicates the consensus NF-kB–binding
sequence. *Mutated (Mut) bases (upper panel). Nuclear extracts were prepared from C2C12 myotubes that had been incubated without (Veh)
and with palmitate for 24 h. They were then subjected to EMSA assay using a biotin-labeled probe (lower panel). For competition assays,
unlabeled oligonucleotides (50-fold) (Self, Mut, and Con) were used as competitors (Comp). NF-kB antibody (Ab) was used for supershift. Lane 1
represented the probe only. siNS, nonspeciﬁc siRNA.
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suppressed SENP2-mediated increase in the mRNA levels
of FAO-associated enzymes and thereby in FAO (Fig. 3D
and E, respectively). On the other hand, the basal FAO
level in the absence of SENP2 overexpression was not
inﬂuenced by knockdown of any of the transcription fac-
tors, including PPARd and PPARg (Supplementary Fig.
4E). These results suggest that SENP2 increases FAO
mainly by promoting PPARd- and PPARg-mediated ex-
pression of FAO-associated enzymes.
For determination of whether SENP2 inﬂuences the
recruitment of PPARd and PPARg to the promoters of
their target genes for the control of FAO, chromatin
immunoprecipitation–coupled quantitative real-time
PCR analysis (ChIP-qPCR) was performed using C2C12
myotubes that had been transfected with Ad-GFP, Ad-
SENP2, and Ad-SENPmt. Overexpression of SENP2, but
not SENP2mt, markedly promoted the binding of PPARd
and PPARg to the CPT1b promoter region, whereas it
showed little or no effect on that of PPARa and PGC1a
(Fig. 3F). Similar results were obtained using the ACSL1
promoter region (Fig. 3G). These results indicate that
SENP2 increases mRNA expression of FAO-associated
enzymes by promoting the recruitment of PPARd and
PPARg to the promoters of the genes.
Next, we tested whether palmitate-induced mRNA level
increase of FAO-associated enzymes was also mediated by
PPARd and PPARg recruitment to their promoters and
whether SENP2 was involved in the process. The recruit-
ment of PPARd and PPARg to the CPT1b or ACSL1 pro-
moters was increased by palmitate and knockdown of
SENP2 suppressed the effect of palmitate (Fig. 3H and I).
These results suggest that SENP2 plays an important role
in the palmitate-induced recruitment of PPARd and PPARg
to the promoters of the FAO-associated enzyme genes.
SENP2 Promotes PPARd Activity by Desumoylation
We have previously shown that SENP2 desumoylates
PPARg and promotes its activity (32). To determine
whether PPARd also is a target for SENP2, we ﬁrst exam-
ined whether PPARd is sumoylated. Sequence analysis
revealed that PPARd contains the MK104LE sequence, which
is conserved in mouse and human and similar to the con-
sensus sumoylation CKXE motif, where C is a hydrophobic
amino acid and X is any amino acid (Fig. 4A). Therefore, we
replaced the Lys104 residue with Arg to test whether the
mutation (K104R) inﬂuences PPARd sumoylation. Overex-
pression of SUMO1 and UBC9 (sumoylation E2 enzyme)
with PPARd, but not with its K104R mutant, dramatically
increased the appearance of slow-migrating PPARd bands
(Fig. 4B). Furthermore, the slow-migrating bands could com-
pletely be eliminated by the expression of SENP2 but not by
SENP2mt (Fig. 4C). These results indicate that PPARd, like
PPARg, serves as a target of SENP2 and its Lys104 residue is
a major SUMO acceptor site. The higher–molecular weight
bands were also detected with anti-ubiquitin antibody as
well as anti-SUMO antibody, and ubiquitination of PPARd
was increased when sumoylation was accompanied (Supple-
mentary Fig. 5A). Therefore, it is possible that sumoylation
of PPARd promotes ubiquitination, which generates multi-
ple high–molecular weight bands. We also conﬁrmed desu-
moylation of endogenous PPARd by SENP2 overexpression
in myotubes (Supplementary Fig. 5B).
Figure 2—SENP2 is responsible for palmitate-mediated increase of FAO. A: Total RNAs were prepared from C2C12 myotubes that had
been treated with 0.25, 0.5, or 1 mmol/L palmitate for 24 h. They were then subjected to real-time PCR (n = 4). *P < 0.05 compared with
untreated cells. B and C: Myotubes were transfected with siRNAs against SENP2 (siSENP2). After incubation for 24 h, they were treated
with 0.5 mmol/L palmitate (n = 5). The mRNA levels for the indicated proteins (B) and FAO (C) were then determined. siNS, nonspeciﬁc
siRNA. *P < 0.05.
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Figure 3—SENP2 increases FAO by promoting PPARd- and PPARg-mediated expression of FAO-associated enzymes. A: Total RNA was
isolated from C2C12 myotubes that had been infected with Ad-GFP or Ad-SENP2 for 3 days and then subjected to microarray. Differentially
expressed genes were identiﬁed as those with false discovery rates <0.05 and fold change larger than the cutoff of 1.5. B: C2C12 myotubes
were infected with Ad-GFP, Ad-SENP1, Ad-SENP2, or Ad-SENP2mt for 3 days. Total RNAs were obtained from the cells and then subjected to
real-time PCR (n = 4). C: Cells prepared as in B were subjected to FAO assay (n = 5). *P < 0.05 compared with Ad-GFP infected cells. D and E:
C2C12 myotubes transfected with the indicated siRNAs were infected with Ad-GFP or Ad-SENP2. siNS, nonspeciﬁc siRNA. After incubation for
48 h, the mRNA levels of FAO-associated enzymes (n = 4) and FAO (n = 6) were determined. *P < 0.05 compared with cells transfected with
nonspeciﬁc siRNA and Ad-SENP2. F and G: C2C12 myotubes infected with Ad-GFP, Ad-SENP2, or Ad-SENP2mt were subjected to ChIP-
qPCR analysis with theCPT1b promoter region (F) and ACSL1 promoter region (G). Data are the means6 SEM (n = 4). *P< 0.05 compared with
Ad-GFP–infected cells. H and I: C2C12 myotubes were treated with siSENP2 for 24 h followed by treatment of palmitate (500 mmol/L) for 24 h
and then subjected to ChIP-qPCR (n = 3). Veh, vehicle. *P< 0.05 compared with nonspeciﬁc siRNA without palmitate. #P< 0.05 compared with
nonspeciﬁc siRNA with palmitate.
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For examination of whether PPARd sumoylation affects
its activity, COS7 cells were transfected with a PPRE-TK-Luc
reporter vector. Note that coexpression of PGC1a was nec-
essary to detect the PPARd activity in nonmuscle COS7
cells, which were used instead of C2C12 myotubes having
very low transfection efﬁciency. Overexpression of SENP2
dramatically increased the activity of PPARd (Fig. 4D). Re-
markably, the activity of sumoylation-deﬁcient K104R seen
without SENP2 was nearly as high as that of wild-type (WT)
PPARd seen with SENP2, indicating that SENP2-mediated
desumoylation is required for PPARd to show its maximal
activity. Taken together, these results indicate that SENP2
promotes the activity of PPARd as well as PPARg through
desumoylation.
SENP2 Overexpression in Muscle Ameliorates High-
Fat Diet–Induced Obesity and Insulin Resistance
To determine whether SENP2 is indeed involved in lipid
metabolism in vivo, we generated muscle-speciﬁc SENP2
transgenic mice (referred to as mSENP2-TG mice) by
inserting the SENP2-FLAG construct to a b-globin gene
Figure 4—SENP2 promotes the PPARd activity by desumoylation. A: The putative sumoylation sequences of human and mouse PPARd
are shown. B: HA-tagged PPARd and its K104R mutant were expressed in MCF7 cells with HisMax-SUMO1 and FLAG-UBC9. Cell lysates
were subjected to immunoprecipitation (IP) with anti-HA antibody followed by Western blotting (WB) with anti-SUMO1 and anti-PPARd
antibodies. Cell lysates were also directly probed with the indicated antibodies. C: HA-PPARd, HisMax-SUMO1, and FLAG-UBC9 were
expressed with Myc-tagged SENP1 or SENP2 or its mutant (SENP2mt). Immunoprecipitation was then carried out as in B. D: COS7 cells
were treated with siRNAs (50 nmol/L) against PPARg to minimize the effect of endogenous PPARg. The following day, cells were trans-
fected with pPPRE-TK–Luc and expression vectors of SENP2, PGC1a, PPARd, or PPARd K104R. Luc activity of cells transfected with
pPPRE-TK-Luc only was expressed as 1.0, and the others were expressed as its relative values (n = 4). *P < 0.05.
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cassette having the MCK promoter (Supplementary Fig.
6A). The SENP2 mRNA was expressed in all types of mus-
cle tissues of mSENP2-TG mice but not in those of WT
mice (Supplementary Fig. 6B). It was not expressed in the
liver or epididymal fat tissues of both the TG and WT
mice (Supplementary Fig. 6C). Consistently, the SENP2
protein could be detected in the skeletal muscle of the
TG mice but not in that of WT mice (Supplementary
Fig. 6D). In addition, the total protein level of SENP2
(i.e., FLAG-tagged and endogenous SENP2) was at least
three- to fourfold higher in the muscle of mSENP2-TG
mice than that of WT mice under both chow- and high-
fat diet (HFD)-fed conditions (Supplementary Fig. 6E).
These results conﬁrmed that the TG mice overexpress
SENP2 in muscle.
Remarkably, the body weight and fat mass of mSENP2-
TG mice were signiﬁcantly lower than those of WT mice
under HFD-fed conditions, whereas lean mass and bone
mineral contents of the TG mice were similar to that of
WT mice (Fig. 5A–D). Analysis by glucose tolerance tests
and insulin tolerance tests revealed that mSENP2-TG
mice show higher glucose tolerance and insulin sensitivity
than WT mice under HFD-fed conditions (Fig. 5E and F).
Moreover, the basal levels of insulin and triglyceride in
the serum of HFD-fed TG mice were much lower than
those of WT mice (Fig. 5G and H). On the other hand,
little or no difference was detected in the serum choles-
terol level under both chow- and HFD-fed conditions (Fig.
5I). Moreover, electron microscopic analysis revealed that
the gastrocnemius muscle of the TG mice contained much
lower fat than that of WT mice under HFD-fed conditions
(Fig. 5J). On the other hand, the fat level in the liver and
fat size of adipose tissues of the TG mice was similar to
that of WT mice under both chow- and HFD-fed condi-
tions (Supplementary Fig. 7A and B). Signiﬁcantly, insulin-
stimulated phosphorylation of insulin receptor substrate 1
and protein kinase B (PKB/Akt) in the gastrocnemius mus-
cle of mSENP2-TG mice was much higher than that of
WT mice under both chow- and HFD-fed conditions (Fig.
5K), suggesting that SENP2 promotes insulin signaling.
Taken together, these results indicate that SENP2 overex-
pression in muscle alleviates HFD-induced obesity and in-
sulin resistance.
SENP2 Overexpression Increases FAO by Upregulating
Expression of FAO-Associated Enzymes in Muscle
Next, we determined the levels of free fatty acids and
triglyceride in the gastrocnemius muscle. While the level
of free fatty acids in the muscle tissue of the TG mice was
similar to that of WT mice (Fig. 6A), the triglyceride level
in the TG mice was signiﬁcantly lower than that of WT
mice under both chow- and HFD-fed conditions (Fig. 6B).
In addition, FAO was markedly increased in the muscle of
the TG mice under both chow- and HFD-fed conditions
compared with that of WT mice (Fig. 6C), and ATP con-
tents were also increased in the muscle of HFD-fed TG
mice (Supplementary Fig. 7C). These results indicate that
the muscle tissues of the TG mice show higher FAO,
which would reduce fat accumulation.
We next examined whether the increase in FAO is
associated with SENP2-mediated changes in the expression
of FAO-associated enzymes (i.e., ACSL1, CPT1b, and UCP3).
Consistent with the results obtained with cell culture
system, the mRNA levels of FAO-associated enzymes were
higher in the gastrocnemius muscle of HFD-fed TG mice
than in that of WT mice (Fig. 6D). In contrast, in the muscle
of chow-fed TG mice, only UCP3 mRNA, but not ACSL1 or
CPT1b mRNA, levels were increased (Fig. 6D). When the
mRNA levels of these FAO-associated enzymes of the WT
mice muscle were compared under different diet conditions,
the levels were similar in chow- and HFD conditions (Fig.
6D), and SENP2 mRNA levels of the WT mice were not
signiﬁcantly affected by diet condition, either (Supplemen-
tary Fig. 7D). In addition, no apparent difference between
mSENP2-TG and WT mice muscles was observed in the
mRNA levels of transcriptional factors, including PPARa,
PPARd, PPARg, and PGC1a in both chow- and HFD-fed
conditions (Fig. 6E). Collectively, these results suggest that
SENP2 plays a critical role in the increase of FAO by in-
ducing the expression of FAO-related enzymes and SENP2
overexpression in muscle alleviates HFD-induced obesity
and insulin resistance.
DISCUSSION
On the basis of the present ﬁndings, we propose a potential
mechanism by which SENP2 regulates lipid metabolism in
skeletal muscle (Fig. 7). Upon saturated free fatty acid stimu-
lation, TLR4/MyD88 activates NF-kB for expression of SENP2
transcripts, which would increase the cellular level of SENP2
protein. This increase leads to desumoylation of PPARd and
PPARg and their recruitment to the promoters of the genes
encoding FAO-associated enzymes, including ASCL1 and
CPT1b. Elevated expression of the enzymes would then pro-
mote FAO (the upper panel). In the muscle of mSENP2-TG
mice, overexpressed SENP2 increases FAO via the same mech-
anism described above but without the need of the signal from
saturated fatty acids. This increase in FAO then results in fat
utilization and suppression of its accumulation, which allevi-
ates HFD-induced obesity and insulin resistance (the lower
panel). These ﬁndings demonstrate that SENP2 serves as an
important regulator of lipid metabolism in muscle.
Several questions may be raised from our data and
model. A question is why SENP2-induced FAO is not
observed in HFD-fed WT mice. In an in vitro C2C12
myotube culture system, palmitate treatment signiﬁcantly
increases SENP2 expression, which increases FAO. In
contrast, SENP2 expression is not substantially increased
in the muscle of HFD-fed mice (Supplementary Figs. 6E
and 7D). Similarly, either FAO or the mRNA levels of ACSL1
and CPT1b are not signiﬁcantly changed by HFD (Fig. 6C
and D). The different results in these models could derive
from other metabolic disturbances associated with chronic
high-fat feeding or from different experimental systems (in
vitro vs. in vivo).
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It is notable that the mRNA levels of UCP3 are higher
in the muscle of chow-fed SENP2-TG mice, but un-
expectedly the mRNA levels of ACSL1 and CPT1b are not
increased (Fig. 6D). These are different from the data
observed in the myotube culture system. Given that
the source of fatty acids available for FAO in the chow-
fed condition is limited, it is conceivable that a certain
level of fatty acid could be required for inducing ACSL1
and CPT1b gene expression. Additionally, a yet uniden-
tiﬁed regulatory system that may suppress ACSL1 or
CPT1b expression independently of SENP2 in the con-
text of in vivo milieu is possibly involved in this event.
Figure 5—Muscle-speciﬁc SENP2 overexpression alleviates HFD-induced obesity and insulin resistance. A: WT and mSENP2-TG (TG) mice
at 8 weeks were fed with a standard chow diet or HFD, consisting of 60% fat and 6.8% sucrose, for the next 12 weeks. Their body weights
were measured every day for 14 weeks (n = 15–20/group). Data are the mean6 SEM. *P< 0.05. B–D: Body fat mass (B), lean mass (C), and
bone mineral contents (BMC) (D) were measured after feeding the mice with chow or HFD for 10 weeks using DXA scanning. *P < 0.05.
E and F: Glucose tolerance test (E) and insulin tolerance test (F) were performed. *P < 0.05. G–I: The levels of insulin (G), triglycerides (H), and
total cholesterol (I) in serum were measured. *P < 0.05. Note that the P values were in comparison with WT mice fed with HFD (B and E–H).
J: Sections of gastrocnemius muscle tissues were obtained and then subjected to electron microscopy. K: Mice were treated with insulin for
20 min before sacriﬁce. Extracts prepared from the gastrocnemius muscle were subjected to immunoblot with respective antibodies.
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Future studies will need to clarify these important
issues.
Another question is whether PPARd and PPARg are
only direct targets of SENP2 to promote FAO in muscle.
The effect of palmitate on FAO is completely abolished by
SENP2 knockdown, while knockdown of SENP2 partially
inhibits palmitate-induced expression of CPT1b and UCP3
(Fig. 2B and C), although CPT1 is known to be the limiting
step of FAO. In addition, knockdown of PPARd or PPARg
efﬁciently, but not completely, suppresses SENP2-
mediated FAO (Fig. 3E). These observations indicate the
possibility that SENP2 regulates the function of FAO-
associated enzymes through direct modiﬁcation, at least
in part. It is also possible that SENP2 controls the expres-
sion or function of another protein(s) that is important
for FAO but not tested in this study. Nevertheless, our
study clearly shows that SENP2 increases FAO mainly by
promoting PPARd- and PPARg-mediated expression of
FAO-associated enzymes.
While sumoylation of PPARg was previously reported,
to our knowledge, we show for the ﬁrst time that
PPARd is sumoylated. Of note was the ﬁnding that
high–molecular weight sumoylated bands of PPARd were
detected (Fig. 4B and C). However, it is unlikely that
PPARd is sumoylated at multiple sites because its
K104R mutation completely abrogated PPARd sumoyla-
tion. The fact that SUMO1 is known to be incapable of
forming a polymeric chain and our result showing that
ubiquitination of PPARd is increased by sumoylation sug-
gest that the high–molecular weight bands consist of
PPARd modiﬁed by both SUMO1 and ubiquitin. In fact,
there are several reports that sumoylation of proteins
promotes their ubiquitination (42–44). Further study
will determine whether the ubiquitination is linked to
proteasome-mediated degradation of PPARd.
PPARd is more abundant than PPARg in muscle, sug-
gesting that the contribution of PPARd in lipid metabo-
lism in muscle could be greater than that of PPARg.
Interestingly, however, the effect of PPARg on gene ex-
pression of FAO-associated enzymes and in turn on FAO
in C2C12 myotubes was nearly similar to that of PPARd
(Fig. 3D and E). Thus, it appears that PPARg, in addition
Figure 6—SENP2 overexpression increases FAO by upregulating expression of FAO-associated enzymes in muscle. A–C: WT and
mSENP2-TG (TG) mice were fed with chow or HFD for 12 weeks. The levels of free fatty acids (FFA) (A), triglycerides (B), and FAO (C )
in their gastrocnemius muscle were determined (n = 8/group). D and E: Total mRNAs were isolated from the muscles of the mice and
subjected to real-time PCR (n = 10–14/group) using primers for FAO-associated enzymes (D) and PPARs and PGC1a (E). The mRNA level
seen in chow-fed WT mice muscle was expressed as 1.0, and the others were expressed as its relative values. Data are the mean 6 SEM.
*P < 0.05 compared with WT mice.
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to PPARd, plays an important role in lipid metabolism in
skeletal muscle. This is further supported by experimental
evidence showing that muscle-speciﬁc deletion of PPARg
results in insulin resistance and promotes adiposity (45,46).
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